ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "High Efficacy of Sofosbuvir/Velpatasvir plus GS-9857 for 12 Weeks in Treatment-experienced Genotype 1-6 HCV-Infected Patients, Including those Previously Treated with Direct-acting Antivirals"
Episode Synopsis
Volume 4, Issue 8, Part 1.Raymond T. Chung, MD from Harvard Medical School interviews Dr. Eric Lawitz from the University of Texas Health Science Center about his presentation: High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated with Direct-Acting Antivirals presented at the April 2016 EASL meeting.The post High Efficacy of Sofosbuvir/Velpatasvir plus GS-9857 for 12 Weeks in Treatment-experienced Genotype 1-6 HCV-Infected Patients, Including those Previously Treated with Direct-acting Antivirals appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information.
More episodes of the podcast eViralHepatitis Review
Medications for CHB
20/10/2022
To Treat or Not To Treat
20/10/2022
HBV & Coinfections
20/10/2022
Hepatitis B: Our Current Understanding
20/10/2022
HBV: Next Steps to a Cure
03/08/2021
Treating HCV in PWID: Best Practices
10/04/2020
HCV: Management Beyond the Liver
04/03/2020
Avoiding “MELD Purgatory”
19/04/2019
Clinical Insight: Engaging PWID in HCV Care
28/12/2018
In God we trust